Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Imeroprubart · 1 trial · 1 indication
Relapse is defined as a worsening (increase) of ≥ 1 point on the adjusted inflammatory neuropathy cause and treatment (aINCAT) score at any time point relative to Period 1 Baseline.
| Arm | Type | Description |
|---|---|---|
| Imeroprubart | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Imeroprubart | DRUG | Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2) |
| Placebo | DRUG | Matching placebo SC QW for 24 weeks (Period 1) |
Inclusion Criteria: * Have met clinical diagnostic criteria for typical CIDP or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP. * Have electrodiagnostic test...
Imeroprubart is an investigational small molecule being developed for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a neurological condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Imeroprubart is being developed by Immunovant, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol IMVT. The company is conducting clinical trials to evaluate the drug for Chronic Inflammatory Demyelinating Polyneuropathy.
Imeroprubart is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. A Phase 2 trial is currently recruiting participants with Chronic Inflammatory Demyelinating Polyneuropathy.
Imeroprubart is being studied in a Phase 2 clinical trial identified as NCT07032662, titled 'Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)'. This randomized, double-blind, placebo-controlled trial is recruiting 162 participants across multiple countries.
The specific molecular target of Imeroprubart has not been disclosed in available information. It is classified as a small molecule and is being investigated for its potential therapeutic effect in Chronic Inflammatory Demyelinating Polyneuropathy.